| T cell growth factor: parameters of production and a quantitative microassay for activity S Gillis, MM Ferm, W Ou, KA Smith The Journal of Immunology 120 (6), 2027-2032, 1978 | 4010 | 1978 |
| Interleukin-2: inception, impact, and implications KA Smith Science 240 (4856), 1169-1176, 1988 | 2976 | 1988 |
| Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy D Finzi, J Blankson, JD Siliciano, JB Margolick, K Chadwick, T Pierson, ... Nature medicine 5 (5), 512-517, 1999 | 2672 | 1999 |
| Long term culture of tumour-specific cytotoxic T cells S Gillis, KA Smith Nature 268 (5616), 154-156, 1977 | 1893 | 1977 |
| T cell growth factor receptors. Quantitation, specificity, and biological relevance RJ Robb, A Munck, KA Smith The Journal of experimental medicine 154 (5), 1455-1474, 1981 | 1448 | 1981 |
| Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. AL Moreira, EP Sampaio, A Zmuidzinas, P Frindt, KA Smith, G Kaplan The Journal of experimental medicine 177 (6), 1675-1680, 1993 | 1326 | 1993 |
| T‐cell growth factor KA Smith Immunological reviews 51 (1), 337-357, 1980 | 1253 | 1980 |
| The interleukin-2 T-cell system: a new cell growth model DA Cantrell, KA Smith Science 224 (4655), 1312-1316, 1984 | 1237 | 1984 |
| A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor WJ Leonard, JM Depper, T Uchiyama, KA Smith, TA Waldmann, ... Nature 300 (5889), 267-269, 1982 | 1077 | 1982 |
| The functional relationship of the interleukins. KA Smith, LB Lachman, JJ Oppenheim, MF Favata The Journal of experimental medicine 151 (6), 1551-1556, 1980 | 888 | 1980 |
| Interleukin 2 KA Smith Annual review of immunology 2 (1), 319-333, 1984 | 845 | 1984 |
| Glucocorticoid-induced inhibition of T cell growth factor production: I. The effect on mitogen-induced lymphocyte proliferation S Gillis, GR Crabtree, KA Smith The Journal of Immunology 123 (4), 1624-1631, 1979 | 801 | 1979 |
| Transient expression of interleukin 2 receptors. Consequences for T cell growth. DA Cantrell, KA Smith The Journal of experimental medicine 158 (6), 1895-1911, 1983 | 788 | 1983 |
| Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. K Teshigawara, HM Wang, K Kato, KA Smith The Journal of experimental medicine 165 (1), 223-238, 1987 | 716 | 1987 |
| Prolonged interleukin-2Rα expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo V Kalia, S Sarkar, S Subramaniam, WN Haining, KA Smith, R Ahmed Immunity 32 (1), 91-103, 2010 | 707 | 2010 |
| Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. SC Meuer, RE Hussey, DA Cantrell, JC Hodgdon, SF Schlossman, ... Proceedings of the National Academy of Sciences 81 (5), 1509-1513, 1984 | 690 | 1984 |
| Interleukin 2 regulates its own receptors. KA Smith, DA Cantrell Proceedings of the National Academy of Sciences 82 (3), 864-868, 1985 | 578 | 1985 |
| Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. MA Caligiuri, A Zmuidzinas, TJ Manley, H Levine, KA Smith, J Ritz The Journal of experimental medicine 171 (5), 1509-1526, 1990 | 549 | 1990 |
| The interleukin 2 receptor. Functional consequences of its bimolecular structure. HM Wang, KA Smith The Journal of experimental medicine 166 (4), 1055-1069, 1987 | 549 | 1987 |
| Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo JN Blattman, JM Grayson, EJ Wherry, SM Kaech, KA Smith, R Ahmed Nature medicine 9 (5), 540-547, 2003 | 476 | 2003 |
